Functional Neuromodulation, a startup backed by Medtronic and the National Institutes of Health, will advance its deep brain stimulation implant into a Phase III trial to treat Alzheimer's disease patients. DBS is a standard treatment for movement disorders, such as Parkinson's disease, but hasn't been widely applied to other brain disorders.
Researchers nabbed a $6.8 million, 5-year grant from the National Institutes of Health to develop technology to predict, track and treat epileptic seizures. The grant is part of the ongoing BRAIN (Brain Research Through Advancing Innovative Neurotechnologies) Initiative launched by President Obama.
The National Institutes of Health called an early halt for an enormous, 9,300+ person trial examining the role of blood pressure intervention due to significant preliminary results. The U.S. agency found that maintaining systolic blood pressure at a lower level than current recommendations reduces rates of heart disease and the risk of death.
The U.S. National Institutes of Health has allocated $48.6 million to fuel the integration of genomic information into electronic health records (EHRs). The NIH is making the cash available in grants to more than 10 research teams, each of which is tasked with investigating a different aspect of the process.
Owlet Baby Care has expanded its Series A round by $6 million. It also picked up another $1 million in a National Institutes of Health grant--to bring its fundraising total to $9.2 million. The startup will use that cash for a fall launch of its Owlet Baby Monitor that is intended to alert parents via smartphone if their baby stops breathing.
A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.
Researchers at the National Institutes of Health reported that a leishmaniasis vaccine based on sand fly saliva has worked well in monkeys.
The FDA, which has been going full bore after offending compounding pharmacies, has now turned its attention to one of its sister agencies. The result is that the National Institutes of Health has closed its Pharmaceutical Development Section after FDA inspectors found "serious manufacturing problems" that resulted in fungal contamination in a drug used in clinical trials.
Newly public genetic information company Invitae has dropped prices for its genetic tests, just as the NIH says it will launch a study of the efficacy of cancer drugs by genetic mutation. Both are a testament to the rapidly evolving role of genetic information in patient treatment.
The National Institutes of Health announced the 13 winning teams of the Neuro Startup Challenge. They were chosen to commercialize its unlicensed technologies to improve brain health.